• Multiomics Used To Stratify Multiple Myeloma Patients Into Affinity Groups

    Bio-IT World | All new multiple myeloma patients being treated at the Tisch Cancer Institute at Mount Sinai are now being assigned to one of 12 subgroups based on shared genetic and molecular features of their disease. The multiple myeloma patient similarity network (MM-PSN) is one of the latest computational modeling tools being used here to translate clinical data into better treatment decision-making in the clinic, and the first to apply multiomics to the stratification of patients with the blood cancer.

    Jan 6, 2022
  • Overlooked Impact Of Cardiometabolic Drugs On The Gut Microbiome

    Bio-IT World | A large-scale study involving more than 2,000 individuals across three countries could help disentangle associations between cardiometabolic disease, the gut microbiome, and metabolic markers in the blood—and, perhaps most importantly, the potential role played by the most prescribed drug treatments.

    Jan 5, 2022
  • Is Excel Holding Back Biopharmaceutical Research?

    Bio-IT World | Data aggregation and consolidation are essential in biopharmaceutical development. Research teams use a wide range of analytical and sensor data from various instruments, which are often spread across multiple sites. These data streams need a common platform to allow scientists to review the data and make decisions. Excel is used to perform this consolidation in many companies, but while access to Excel is convenient, this software is the root cause of many data management problems.

    Jan 3, 2022
  • Follow the Money: AI-Driven Talent Engagement, Cancer Center Funding, Maternal Health, More

    Bio-IT World | AI used in talent engagement and communication and in the development of therapeutic antibodies; women’s health, maternal health, and contraceptive technologies

    Dec 28, 2021
  • Top Stories of 2021: Efforts to Overcome Aging, High-Def Spatial Transcriptomics, an NIH Push to Cure HIV. And a Little More COVID

    Bio-IT World | Some of our biggest stories of the year were about the promise to limit aging through epigenetic reprogramming, new inhibitors to prevent age-associated cognitive decline, and improved single-cell sequencing technologies. Of course interest in COVID-19 remained, and we went in depth on mRNA vaccines and talked digital transformation at Pfizer and GSK in this pandemic era.

    Dec 27, 2021
  • PacBio’s Precision Health Partnership, NVIDIA’s Open Source SDK, More

    Bio-IT World | Singular Genomics launches new benchtop sequencer, collaborations in neuropsychiatry, lactation research, skin health, chronic pain, and SARS-CoV-2 vaccines, Insilico Medicine announces first-in-human trial of an AI-developed drug. Plus new products from PerkinElmer, Thermo Fisher, Genomenon, and more.

    Dec 22, 2021
  • Big Data vs. Alzheimer’s

    Bio-IT World | Sudeshna Das directs the data core of the Massachusetts Alzheimer’s Disease Research Center (MADRC). She recently sat down with BioTeam to discuss how MGH is collecting and working with enormous datasets to push back against Alzheimer’s.

    Dec 21, 2021
  • Recursion, Roche-Genentech, Bayer Launch Multi-Million Dollar Collaborations

    Bio-IT World | Last week, Recursion announced two collaborations: a new collaboration with Roche and Genentech to leverage technology-enabled drug discovery through the Recursion Operating System (OS), and an expansion of an existing Bayer collaboration focused on inferential search.

    Dec 16, 2021
  • Nautilus Biotechnology Taking Protein Analysis To The Single-Molecule Level

    Bio-IT World | A growing number of companies are endeavoring to replicate the success of gene sequencing juggernaut Illumina in the burgeoning field of proteomics. A top contender is Nautilus Biotechnology, which has spent the past few years drumming up excitement about the potential for comprehensively profiled proteins to make therapeutic and diagnostic development more effective and time efficient.

    Dec 15, 2021
  • Seven Bridges Launches the Unified Patient Network With Genomic, EHR Data

    Bio-IT World | Seven Bridges Genomics has launched a new subsidiary, the Unified Patient Network (UPN), to facilitate clinical research and collaboration between participating health systems and biopharma companies. The UPN will combine de-identified sequencing data and EHR content for five million patients and allow biopharma companies to license cohorts from that dataset for research. Licensing fees from biopharma will fund the network.

    Dec 14, 2021
  • Why Mass Spectrometry Is Taking Over Affinity-based Approaches In Plasma Proteomics

    Bio-IT World | The demand for proteomics studies has increased in recent years, with growing emphasis on datasets capturing vast amounts of proteomics data from large cohorts of patients, with thousands of proteins measured in each person. In part, this has been led by developments in computational methods, like deep learning to analyze data, as well as advancements in sample analytical methodologies.

    Dec 10, 2021
  • Harvard and MIT Researchers Pursue Improved RNA and Cellular Therapies with eToehold Technology

    Bio-IT World | A group of cell engineers and synthetic biologists at Harvard University and Massachusetts Institute of Technology (MIT) has developed a tech tool called “eToeholds” that could help improve the safety and efficacy of RNA and cell therapies, in addition to enabling new forms of detection.

    Dec 9, 2021
  • Cupping Technique Has Standout Performance In DNA Vaccine Studies

    Bio-IT World | The ultimate challenge of drug delivery—successfully getting a medicine into a cell—has several lines of pursuit when it comes to nucleic acid-based vaccines and the latest and greatest is an ancient cupping technique which, at least in rodents, is almost unfathomably good at driving immune responses. To say the Rutgers University research team was surprised by the finding would be an understatement.

    Dec 8, 2021
  • Clive Brown on Field Biopsies, New Chemistry, Short Reads

    Bio-IT World | At Oxford Nanopore’s virtual Community Meeting this week, CTO Clive Brown presented new chemistries, previewed the Apple iPad Pro-powered Mk1D with an integrated MinION, teased the diagnostic capacities of “outy” sequencing, unveiled a browser base caller, and more.

    Dec 3, 2021
  • Follow the Money: Cloud R&D, Generative Biology, Robotics

    Bio-IT World | Platforms for machine-learning generative biology and cloud R&D, drug delivery chip for therapies at the tumor site, and AI-driven drug discovery and robotics.

    Dec 2, 2021
  • Cloud Hygiene and Cost Optimization at Johnson & Johnson

    Bio-IT World | TRENDS FROM THE TRENCHES—Tom Messina has worked in various roles for Johnson & Johnson dating back to 1999 and is currently an IT Director in J&J’s Pharmaceutical R&D division, Janssen. BioTeam had a chance to speak with Tom recently to appreciate how J&J is leveraging cloud compute and storage resources to maximize innovation and growth while controlling costs.

    Dec 1, 2021
  • Gilead Chooses AWS, Illumina, Sequoia Fund Chinese Startups, More

    Bio-IT World | Illumina powers the Canadian COVID-19 Genomics Network, organ-on-a-chip explores infectious disease, and cell analysis acquisitions. Plus new products from PerkinElmer, Bio-Rad, Roswell Biotechnologies, Genialis, and more.

    Nov 30, 2021
  • Building the Data Foundation for Faster Time to Science in Healthcare

    Bio-IT World | Genomics and artificial intelligence (AI) are key to this quest and at-scale advancement of personalized medicine. Both, however, require liquid data and modern data infrastructure that re-imagines the role of data and how it is used.

    Nov 23, 2021
  • Gut Microbiome Linked To Aggressive Prostate Cancer

    Bio-IT World | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story.

    Nov 22, 2021
  • Biopharma’s Dark Data Problem

    Bio-IT World | Worldwide spending on pharmaceutical R&D will reach $230 billion by 2026. So with investment dollars flowing in and R&D continuing an upward trajectory all should be well, right? Well… not exactly. Like many industries, pharmaceutical companies are facing a data problem—a dark data problem.

    Nov 19, 2021